TGF-beta/Smad Agonists

Cat.No.	Product Name	Information	Product Use Citations
S6654	SRI-011381 (C381)	SRI-011381 (C381), a novel agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease, physically targets the lysosome, promotes lysosomal acidification, increases breakdown of lysosomal cargo, and improves lysosome resilience to damage.	Noncoding RNA Res, 2025, 13:1-14 SLAS Technol, 2024, 29(5):100190 Dis Model Mech, 2022, dmm.046979
E4798	SRI-011381 hydrochloride	SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer's disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin.	Molecular Cancer, 2023, 66 Experimental and Therapeutic Medicine, 2021 Dec, 1414 Experimental and Therapeutic Medicine, 2021, 1414
S0523	SB 4	SB 4 is a potent and selective agonist of bone morphogenetic protein 4 (BMP4) signaling with EC50 of 74 nM. This compound enhances canonical BMP signaling and activates SMAD-1/5/9 phosphorylation. As an agonist of the BMP signaling pathway, this chemical can significantly upregulate the expression levels of classical BMP4 downstream target genes (such as DNA binding inhibitors Id1 and Id3).

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S6654

SRI-011381 (C381)

SRI-011381 (C381), a novel agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease, physically targets the lysosome, promotes lysosomal acidification, increases breakdown of lysosomal cargo, and improves lysosome resilience to damage.

Noncoding RNA Res, 2025, 13:1-14

SLAS Technol, 2024, 29(5):100190

Dis Model Mech, 2022, dmm.046979

E4798

SRI-011381 hydrochloride

SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer's disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin.

Molecular Cancer, 2023, 66

Experimental and Therapeutic Medicine, 2021 Dec, 1414

Experimental and Therapeutic Medicine, 2021, 1414

S0523

SB 4

SB 4 is a potent and selective agonist of bone morphogenetic protein 4 (BMP4) signaling with EC50 of 74 nM. This compound enhances canonical BMP signaling and activates SMAD-1/5/9 phosphorylation. As an agonist of the BMP signaling pathway, this chemical can significantly upregulate the expression levels of classical BMP4 downstream target genes (such as DNA binding inhibitors Id1 and Id3).